VLS Tirzepatide 20mg Peptide Injection Pen

Price 4650.0 INR/ Box

Get a Price/Quote

MOQ : 5 Boxes

VLS Tirzepatide 20mg Peptide Injection Pen Specification

Origin of Medicine
india

Pacakaging (Quantity Per Box)
1

Life Span
5 Years

Dosage Form
20mg

Brand Name
VLS Tirzepatide Pen

Drug Type
Other

Ingredients
Tirzepatide Peptide is a synthetic peptide therapeutic that belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual-agonist approach distinguishes tirzepatide from earlier single-receptor-targeting peptides and represents a significant advancement in metabolic medicine.

Physical Form
Other

Function
Reduce Weight

Recommended For
For Weight Loss

Dosage
20mg

Suitable For
Teenagers, Women, Adults

Quantity
50000 Boxes

VLS Tirzepatide 20mg Peptide Injection Pen Trade Information

Minimum Order Quantity
5 Boxes

FOB Port
UPS, EMS, DHL

Payment Terms
Paypal, Cash Against Delivery (CAD), Western Union

Supply Ability
50000 Boxes Per Day

Delivery Time
5 Days

Sample Policy
Contact us for information regarding our sample policy

Packaging Details
Sealed Box

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

VLS Tirzepatide 20mg Peptide Injection Pen About

Tirzepatide Peptide

Tirzepatide Peptide is a synthetic peptide therapeutic that belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual-agonist approach distinguishes tirzepatide from earlier single-receptor-targeting peptides and represents a significant advancement in metabolic medicine.

The medication is engineered as a single peptide molecule that maintains stability appropriate for pharmaceutical use while providing sustained therapeutic effects. Its molecular structure has been specifically designed to activate both GIP and GLP-1 receptors, offering what researchers describe as a more comprehensive intervention in metabolic pathways compared to single-agonist agents.

Tell us about your requirement